文献速递临床试验与 GCP

健脾生髓膏治疗非小细胞肺癌化疗相关性疲乏的随机安慰剂对照试验方案

Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial.
PubMed 文献 · Trials · 2020-01-16

本研究为前瞻性随机安慰剂对照试验,旨在评估健脾生髓膏(JPSS)治疗非小细胞肺癌(NSCLC)化疗相关性疲乏(CRF)的疗效与安全性。NSCLC伴CRF患者按1:1随机分为JPSS组和安慰剂组,在两个化疗周期中口服JPSS或安慰剂15g每日两次,主要终点为基线至第42天修订版Piper疲乏量表评分差值。

要点

  • JPSS组与安慰剂组按1:1随机,在TP/DP/AP化疗第6至20天口服15g每日两次。
  • 主要终点为基线至第42天修订版Piper疲乏量表评分差值。
  • 次要终点包括生活质量(EORTC QLQ-LC43)、ECOG体能状态和中医证候评分。

核心结论

  • 本试验将评估JPSS治疗NSCLC患者CRF的疗效与安全性。

研究设计与样本

  • 前瞻性、随机、安慰剂对照试验,在广州中医药大学第一附属医院开展。
  • NSCLC伴CRF患者按1:1随机分为JPSS组和安慰剂组。

关键数值与推荐

  • JPSS组口服JPSS膏15g每日两次,安慰剂组口服安慰剂15g每日两次,从第6天至第20天,共两个化疗周期。
  • 主要终点为基线(干预开始前一天)至第42天修订版Piper疲乏量表评分差值。
  • 次要终点包括EORTC QLQ-LC43生活质量、ECOG体能状态和中医证候评分,同时评估治疗毒性。
  • 所有结局在基线、第6天、第21天和第42天测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy-related fatigue (CRF) is a common symptom in non-small cell lung cancer (NSCLC) patients. A Chinese herbal formula cream for oral application, called Jianpishengsui (JPSS), is extensively used in the First Affiliated Hospital of Guangzhou University of Chinese Medicine as an internal preparation for CRF and is associated with a promising response. Due to the lack of high-quality clinical evidence, a randomized placebo-controlled trial is required to assess the efficacy and safety of JPSS. METHODS/DESIGN: The efficacy and safety of JPSS herbal formula cream will be evaluated through a prospective, randomized, placebo-controlled trial conducted in the First Affiliated Hospital of Guangzhou University of Chinese Medicine. NSCLC patients with CRF will be randomized into two groups at a ratio of 1:1. Each group will receive either 15 g of the oral JPSS herbal formula cream or placebo twice a day from day 6 to day 20 during two courses of paclitaxel + platinum/docetaxel + platinum/pemetrexed + platinum (TP/DP/AP) chemotherapy. The primary endpoint is the difference in the degree of fatigue between baseline (the day before the start of the intervention) and day 42, which will be assessed by the Revised Piper Fatigue Scale score. The secondary endpoints are quality of life (measured by the 43-item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer C43), Eastern Cooperative Oncology Group Performance Status, and Traditional Chinese Medicine syndrome score. The toxicity of the treatments will also be evaluated at the same time. All outcomes will be measured at baseline, day 6, day 21, and day 42 of the treatment. DISCUSSION: This randomized trial will investigate the efficacy and safety of JPSS applied for CRF in patients with NSCLC. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1900023451. Registered on 28 May 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Xiao Z, Hu L, Lin J, et al. Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial. Trials. 2020. PMID: 31948475. doi:10.1186/s13063-019-3982-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。